GMP regulations (Good Manufacturing Practice) are the set of requirements ensuring that a medicinal product is consistently produced and controlled to the quality standards appropriate to its intended use and marketing authorization. They are not merely a technical reference: in Europe and the United States they are legally binding, and violations can lead to inspection findings, suspension of the manufacturing authorization or batch recalls. In this article we look at what GMP is, where it comes from, which documents define it and — above all — how to apply it in practice in your company.
GMP regulations: what they are and what they are for
GMP rules are built on a simple principle: the quality of a medicine cannot be verified only by testing the finished product — it must be built into the entire process. Quality control on a sample alone will not catch a localized contamination, a label mix-up or a recording error: you need a system that oversees every stage, from receipt of raw materials to batch shipment.
That is why GMP covers every element that influences product quality:
- Personnel: qualifications, documented training, defined responsibilities (including key figures such as the Qualified Person in the EU);
- Premises and equipment: design, qualification, maintenance and cleaning adequate to prevent contamination and cross-contamination;
- Documentation: specifications, procedures (SOPs), batch records and records that make every operation traceable and reconstructable;
- Production and controls: validated processes, in-process controls, deviation management and change control;
- Quality: batch release, complaint handling, recalls, self-inspections and continuous improvement.
The regulatory framework: EudraLex, FDA, WHO and PIC/S
The term "GMP" refers to a family of regulatory references, not a single document. There are four main systems a QA/QC professional will encounter.
| System | Main reference | Scope of application |
|---|---|---|
| European Union | EudraLex Volume 4 (EU GMP Guidelines) | Human and veterinary medicinal products manufactured or imported into the EU; national authorities conduct GMP inspections |
| United States | FDA cGMP – 21 CFR Part 210 and Part 211 | Drugs manufactured or distributed on the US market; the "c" for current requires systems and technologies to be kept up to date |
| WHO | WHO GMP "Main Principles" (TRS 986, Annex 2) | Reference for national authorities in many countries and for WHO prequalification programmes |
| PIC/S | PIC/S GMP Guide (PE 009) | Harmonization of inspections among participating authorities; the guide is aligned with EU GMP |
EudraLex Volume 4 — the day-to-day reference for anyone working in Europe — is structured in three parts plus the Annexes: Part I (Chapters 1–9) covers the basic requirements for medicinal products, from the pharmaceutical quality system to self-inspections; Part II covers active substances (APIs) and derives from the ICH Q7 guideline; Part III collects supporting documents such as the Site Master File and the ICH Q9 and Q10 guidelines. The Annexes detail specific areas: among the most relevant, Annex 1 for sterile medicinal products (2022 revision, applicable since 25 August 2023), Annex 11 for computerised systems, Annex 15 for qualification and validation and Annex 16 for QP certification of batches.
If you work in QA, QC or production and want to stay on top of GMP, inspections and regulatory updates with a practical slant, subscribe to The Pragmatic GMP, our free weekly newsletter: one GMP topic every week, explained in operational terms with no fluff.
The fundamental principles of GMP
Beyond the formal differences between the various systems, the underlying principles are shared and form the common "language" of any pharmaceutical site:
- Write what you do, do what you have written, document it: every critical activity is defined by an approved procedure and recorded at the time of execution;
- Validated processes: the ability of a process to deliver a compliant product must be demonstrated with evidence, not assumed;
- Quality built into the process: finished-product testing confirms — it does not replace — control of the manufacturing steps;
- Full traceability: from raw material batch to patient, every step must be reconstructable;
- Risk management: decisions rely on documented risk assessments (the ICH Q9 approach);
- Qualified and trained personnel: training is continuous, documented and verified for effectiveness;
- Continuous improvement: deviations, CAPAs, trends and Product Quality Reviews feed a system that learns.
How to implement GMP regulations in your company
Moving from the regulatory text to daily practice is the real test. An effective implementation (or consolidation) journey covers at least these points:
- Establish a Pharmaceutical Quality System in line with Chapter 1 of EU GMP and ICH Q10, with clear responsibilities and periodic management review;
- Map processes and procedures: every GMP-impacting activity must have an approved, up-to-date SOP known to those who perform it;
- Qualify premises, equipment and suppliers: IQ/OQ/PQ qualification per Annex 15 and a risk-based vendor qualification programme;
- Safeguard documentation and data integrity: good documentation practices, audit trails and ALCOA+ controls on paper and on computerised systems alike;
- Manage deviations, CAPAs and change control as structured processes, with root cause analysis and effectiveness checks;
- Build a risk-based self-inspection programme that simulates the inspector's eye before the real inspection arrives;
- Train and requalify personnel, measuring the effectiveness of training and not just its delivery.
GMP compliance is periodically verified by the authorities: in Europe, a successful inspection leads to a GMP certificate recorded in the public EudraGMDP database, while a negative outcome can result in a statement of non-compliance with immediate consequences for production and supply. Being inspection-ready is therefore not an extraordinary event, but the natural outcome of a system that works every day.
A frequent mistake is treating GMP as a documentation project: producing hundreds of procedures nobody actually follows is, in an inspector's eyes, an aggravating factor rather than a mitigating one. The goal is a lean, coherent, defensible system in which every document answers a real risk.
GuideGxP recommendation
Our practical advice: start from a gap analysis, not from procedures. Compare what the company actually does with the chapters of EU GMP Part I and with the Annexes applicable to your process, rank the gaps by risk and build a remediation plan with owners and deadlines. Involve production and QC from day one: GMP applied only by QA stays on paper. And remember that in an inspection it is not quoting the rule that counts, but demonstrating with evidence that the system works.
For those who have to lead this journey in their company, our Operational Guide to the QA Manager Role in Pharma translates GMP requirements into ready-to-use processes, checklists and tools designed to be defensible in audits.
